/ Health and Fitness

CBD Oil and Drug Testing

Recently, along with increased promotion of CBD products, there have been mounting concerns relating to this drug. The following is important information assembled from nationally recognized CBD studies and other reputable publications. We hope this article may shed light on some questions we have received.

CBD Oil and Drug Testing:

According U.S. Government Definitions “The term ‘hemp’ means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis” (Agricultural Marketing Act, p. 59).

In common language, Hemp is a Cannabis plant which contains .3% or less of THC. To further describe, the only sizable legal distinction between Hemp and Marijuana is the amount of THC, as they are all the same “type of plant”, or genus.

DEA comments on CBD Oil (cannabidiol): “For practical purposes, all extracts that contain CBD will CBD Oil and Drug Testing: also contain at least small amounts of other cannabinoids (THC). Although it might be theoretically possible to produce a CBD extract that contains absolutely no amounts of other cannabinoids (THC), the DEA is not aware of any industrially-utilized methods that have achieved this result” (Drug Enforcement Administration, 2016).

This means that there are no CBD-only products on the market nor any way to make CBD products completely devoid of THC- even if they are advertised as such. When a product makes the claim “0% THC” or “THC Free”, this can still include “small” amounts of THC- the actual percentage does not need to be defined. Additionally, there currently aren’t any laws in place to define terms such as “Pure”, “CBD Isolate”, or “Natural”. With this information, please be aware that CBD oil may still result in a positive drug test, especially in “large doses”. Ironically, according to the World Health Organization, doses of CBD oil are also not standardized (White, p.11). For more information, please consult your health care professional.

Written and produced by The Lexington Group EAP.

Bailey, D. G., Malcolm, J., Arnold, O. and David Spence, J. (1998), Grapefruit juice–drug interactions. British Journal of Clinical Pharmacology, 46: 101-110. doi:10.1046/j.1365-2125.1998.00764.x

Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). “https://drug-interactions.medicine.iu.edu” Accessed 27 Sept. 2019.

Lynch, Tom, ParmD, and Amy Price, MD. “The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects.” American Family Physician 3rd ser. 76 (2007): 391-396. American Academy of Family Physicians. Eastern Virginia Medical School, 1 Aug. 2007. Web. 27 Sept. 2019. <https://www.aafp.org/afp/2007/0801/p391.pdf>.

United States Department of Justice. Drug Enforcement Administration. Diversion Control Division. Rosenberg, Chuck. Rules – 2016. Government Publishing Office, 14 Dec. 2016. <https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1214.htm>.

United States Health Regulation and Licensing Administration. Medical Marijuana Program. Medical Cannabis Adverse Effects & Drug Interactions. Adriane Fugh-Berman, Susan Wood, Mikhail Kogan, Donald Abrams, Mary Lynn Mathre, Andrew Robie, Janani Raveendran, Kofi Onumah, Rikin S. Mehta, Shauna White, and Jawara Kasimu-Graham. Department of Health, n.d. Web. 27 Sept. 2019. <https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Medical%20Cannabis%20Adverse%20Effects%20and%20Drug%20Interactions_0.pdf>.

United States Senate Committee on Agriculture, Nutrition, and Forestry. Agricultural Marketing Act of 1946. (Title II, Subtitle G, Sec. 297A). Government Publishing Office, 20 Dec. 2018. <https://www.agriculture.senate.gov/imo/media/doc/Agricultural%20Marketing%20Act%20Of%201946.pdf>.

White, Jason, Sharon Walsh, Susanna Babalonis, and J. Rehm. Critical Review Report. Rep. World Health Organization, 4 June 2018. Web. 27 Sept. 2019. <https://
www.who.int/medicines/access/controlled-substances/WHOCBDReportMay2018-2.pdf?ua=1>.

Share this Post